![]() |
市場調查報告書
商品編碼
1499422
全球腸道疾病檢測市場:按產品、疾病類型、診斷技術和檢測地點 - 預測(2024-2030)Enteric Disease Testing Market by Product (Consumables, Kits, Reagents), Disease Type (Bacterial, Parasitic, Viral), Diagnostic Techniques, Testing Site - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
預計2023年全球腸道疾病檢測市場規模為43.1億美元,2024年達45.4億美元,2030年達62.6億美元,複合年成長率為5.47%。
腸道疾病檢測包括各種診斷程序,旨在識別影響胃腸道感染的感染疾病。隨著腸道疾病的全球流行、診斷技術、意識和醫療保健支出的進步,對腸道疾病檢測的需求持續成長,因為早期和準確的診斷在管理和預防此類疾病的傳播方面發揮關鍵作用。然而,他們面臨著挑戰,例如與先進測試技術相關的高成本、資源匱乏環境中的訪問受限以及需要熟練人員來執行和解釋測試。為了解決這些問題,人們持續專注於開發具有成本效益且易於使用的診斷解決方案,這些解決方案可以廣泛部署,包括在資源有限的環境中。分子診斷、就地檢驗以及人工智慧和機器學習的應用相結合,提高檢測的準確性和速度,預計將使檢測程式多樣化。
主要市場統計 | |
---|---|
基準年[2023] | 43.1億美元 |
預計年份 [2024] | 45.4億美元 |
預測年份 [2030] | 62.6億美元 |
複合年成長率(%) | 5.47% |
區域洞察
在強大的醫療保健系統和高昂的醫療成本的推動下,美洲,特別是美國和加拿大,先進診斷解決方案的採用率很高,包括分子診斷和就地檢驗。該地區的公司享有有利的法規環境和大量的研發投資,使他們能夠快速創新並生產腸道疾病檢測解決方案。在亞太地區,由於人們對霍亂和傷寒等疾病的認知不斷提高以及醫療費用不斷上漲,對腸道疾病診斷的需求不斷增加。然而,這個市場的特點是先進和傳統診斷方法的混合,並且各國之間的醫療基礎設施存在顯著差異。亞太地區的生產正在擴大,當地企業與成熟的全球企業一起崛起。歐洲、中東和非洲是多樣化的,西歐市場高度發達,採用了尖端的診斷技術,而非洲和中東的一些國家獲得腸道疾病檢測的機會有限,我們正在解決與採購和檢測相關的問題。方便。歐洲、中東和非洲的法規環境差異很大,影響了新技術的採用速度。在歐洲、中東和非洲營運的公司平衡技術創新和具有成本效益的生產,以滿足不同患者群體的需求。
FPNV定位矩陣
FPNV定位矩陣對於評估供應商在腸道疾病檢測市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢查了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對腸道疾病檢測市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他關鍵指標。此外,該分析還提供了對該領域競爭性質的寶貴見解,包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對當前腸道疾病檢測市場地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[198 Pages Report] The Enteric Disease Testing Market size was estimated at USD 4.31 billion in 2023 and expected to reach USD 4.54 billion in 2024, at a CAGR 5.47% to reach USD 6.26 billion by 2030.
Enteric disease testing encompasses a variety of diagnostic procedures aimed at identifying pathogens that cause infectious diseases affecting the gastrointestinal tract. Given the critical role of early and accurate diagnosis in managing and preventing the spread of these diseases, the need for enteric disease testing is driven by factors such as the growing global prevalence of enteric diseases, advancements in diagnostic technologies, and increased awareness and healthcare spending. However, the practice faces challenges such as the high costs associated with advanced testing technologies, limited accessibility in low-resource settings, and the need for skilled personnel to conduct and interpret tests. To address these issues, there is an ongoing focus on developing cost-effective and user-friendly diagnostic solutions that can be deployed widely, including in resource-constrained environments. The integration of molecular diagnostics, point-of-care testing, and the application of artificial intelligence and machine learning to improve test accuracy and speed is expected to diversify the testing procedures.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 4.31 billion |
Estimated Year [2024] | USD 4.54 billion |
Forecast Year [2030] | USD 6.26 billion |
CAGR (%) | 5.47% |
Regional Insights
In the Americas, especially the United States and Canada, there is a high adoption rate of advanced diagnostic solutions, including molecular diagnostics and point-of-care testing, driven by robust healthcare systems and high healthcare expenditure. Companies in this region benefit from a conducive regulatory environment and significant investment in R&D, leading to rapid innovation and production of enteric disease testing solutions. The APAC region has a growing demand for enteric disease diagnostics due to increasing awareness of diseases such as cholera and typhoid coupled with rising healthcare spending. However, the market is characterized by a mix of advanced and traditional diagnostic practices, with significant variations in healthcare infrastructure across countries. Production in APAC is growing, with local companies emerging alongside established global players. EMEA presents a diverse picture, with highly developed markets in Western Europe employing cutting-edge diagnostic technologies while countries in Africa and parts of the Middle East grapple with challenges related to access and affordability of enteric disease testing. Regulatory environments across EMEA vary widely, affecting the pace of adoption of new technologies. Companies operating in EMEA are balancing innovation with cost-effective production to meet the needs of a diverse patient population.
Market Insights
The market dynamics represent an ever-changing landscape of the Enteric Disease Testing Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Enteric Disease Testing Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Enteric Disease Testing Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
FDA Clears MeMed BV Direct from Whole Blood
MeMed announced that its innovative MeMed BV test, designed for rapid differentiation between bacterial and viral infections, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for whole blood samples. This significant milestone allows healthcare professionals to leverage the MeMed Key analyzer, a leading-edge point-of-care device, to diagnose infections accurately in as little as 15 minutes. This breakthrough underscores MeMed's commitment to advancing host response technology and improving patient care by enabling timely and precise treatment decisions. [Published On: 2023-07-19]
Avacta Acquires European Diagnostic Test Maker
Avacta Group, a notable entity in the biotechnology sector, strategically expanded its portfolio by acquiring Coris Bioconcept SRL, a distinguished European producer of rapid diagnostic test kits. Coris Bioconcept specializes in developing, manufacturing, and commercializing lateral flow tests primarily intended for use by healthcare professionals. The company boasts a robust global distribution network, reaching markets across Europe, Asia, South America, Africa, and Oceania, enhancing its presence and operational reach in diagnostic testing. [Published On: 2023-06-01]
Merck Strengthens Immunology Pipeline with Acquisition of Prometheus Biosciences, Inc.
Merck, internationally known as MSD, announced its strategic move to acquire Prometheus Biosciences, Inc., a company in the biotechnological realm focusing on precision medicine methodologies for immune-mediated diseases. This acquisition set the transaction at an impressive total equity value of around USD 10.8 billion. Prometheus, recognized for its innovative approach to developing therapeutic and companion diagnostic solutions, is currently in the clinical stage. This partnership underscores Merck's commitment to advancing healthcare solutions by integrating cutting-edge technology and scientific research into its comprehensive portfolio. [Published On: 2023-04-16]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Enteric Disease Testing Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Enteric Disease Testing Market, highlighting leading vendors and their innovative profiles. These include 3M Company, Abbott Laboratories, Als Limited, Asure Quality, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerica Inc., bioMerieux SA, Bureau Veritas Group, Cepheid Inc., Coris BioConcept SPRL, DiaSorin, Eurofins Scientific SE, Hardy Diagnostics, Intertek Group PLC, Merck & Co., Inc., Merck KGAA, Meridian Bioscience Inc., Merieux NutriSciences Corporation, Neogen Corporation, Nova Biologicals, Perkinelmer, Inc., Qiagen N.V., Quest Diagnostics, Romer Labs Division Holding GmbH, SGS SA, Symbio Laboratories, Thermo Fisher Scientific Inc., Trinity Biotech PLC, and TUV SUD AG.
Market Segmentation & Coverage